Annovis Bio gets NYSE notice for falling below market cap and equity thresholds

Annovis Bio, Inc. (NYSE: ANVS) said on October 30, 2026 that it received a notice from the New York Stock Exchange on October 29, 2026 stating it is no longer in compliance with continued listing standards under Section 802.01B of the NYSE's Listed Company Manual. The notice cited the company's average market capitalization over a consecutive 30 trading-day period falling below $50 million while its stockholders' equity was also below $50 million.¹

As of October 28, 2026, the company's 30 trading-day average market capitalization was approximately $48.4 million, and its last reported stockholders' deficit as of June 30, 2026 was approximately $(4.3) million.¹

Annovis said it will submit a plan within 45 days of the notice outlining definitive action to bring it back into conformity with Section 802.01B within 9 months of receiving the notice, and the NYSE will then have 45 days to determine whether the plan reasonably demonstrates the company's ability to regain compliance within that 9-month window.¹ If the plan is not submitted on time or is not accepted, the NYSE will initiate delisting proceedings.¹ Only if the NYSE accepts the plan will Annovis common stock continue to be listed and traded on the exchange during the cure period, subject to compliance with the plan and other listing standards.¹ If the company fails to comply with the plan or does not meet listing standards by the end of the 9-month cure period, it will face prompt initiation of NYSE suspension and delisting procedures.¹

The notice has no immediate effect on the listing of the stock, which will continue trading as "ANVS," though the trading symbol will carry an added ".BC" designation to show the stock is below NYSE listing criteria.¹ The company said the notice does not affect its business operations, SEC reporting obligations, or trigger any default under its material debt or other agreements.¹